AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Boston Trust Walden Corp

Boston Trust Walden Corp boosted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 13.0% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 6,166 shares of the company’s stock after acquiring an additional 711 shares during the quarter. Boston Trust Walden Corp’s holdings in AstraZeneca were worth $480,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Creative Planning lifted its position in AstraZeneca by 8.0% during the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after acquiring an additional 16,692 shares during the period. TD Asset Management Inc lifted its position in AstraZeneca by 8.6% during the 1st quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock worth $104,160,000 after acquiring an additional 121,876 shares during the period. Northcape Wealth Management LLC acquired a new stake in AstraZeneca during the 2nd quarter worth about $269,000. Wealthcare Advisory Partners LLC lifted its position in AstraZeneca by 9.7% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock worth $416,000 after acquiring an additional 543 shares during the period. Finally, Cetera Advisors LLC lifted its position in AstraZeneca by 124.5% during the 1st quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock worth $6,657,000 after acquiring an additional 54,488 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Finally, TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

NASDAQ AZN opened at $75.05 on Monday. The stock has a market capitalization of $232.70 billion, a price-to-earnings ratio of 36.26, a PEG ratio of 1.39 and a beta of 0.46. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a 50-day moving average of $80.40 and a 200 day moving average of $78.59.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. The company had revenue of $12.45 billion during the quarter, compared to analysts’ expectations of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. AstraZeneca’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.08 EPS. Sell-side analysts anticipate that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.